260 related articles for article (PubMed ID: 37869006)
1. Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors.
Zeng L; Ma G; Chen K; Zhou Q
Front Immunol; 2023; 14():1242336. PubMed ID: 37869006
[TBL] [Abstract][Full Text] [Related]
2. Immune-related adverse events: A bibliometric analysis.
Jiang ST; Liu YG; Zhang L; Sang XT; Xu YY; Lu X
Front Immunol; 2022; 13():1096806. PubMed ID: 36591239
[TBL] [Abstract][Full Text] [Related]
3. A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011-2021.
Zhang H; Shi Y; Ying J; Chen Y; Guo R; Zhao X; Jia L; Xiong J; Jiang F
Front Endocrinol (Lausanne); 2023; 14():1164692. PubMed ID: 37152956
[TBL] [Abstract][Full Text] [Related]
4. Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis.
Xu Y; Jiang Z; Kuang X; Chen X; Liu H
J Med Internet Res; 2022 Jun; 24(6):e32728. PubMed ID: 35759331
[TBL] [Abstract][Full Text] [Related]
5. Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis.
Su Y; Ruan Z; Wang R; Hao S; Tang Y; Huang X; Gao T; Li Z; Chang T
Front Immunol; 2022; 13():998217. PubMed ID: 36248874
[TBL] [Abstract][Full Text] [Related]
6. Global research hotspots and frontiers of myasthenia gravis from 2002 to 2021: A bibliometric study.
Yang J; Wu J; Han T; Lu H; Li F; Li L; Su S; Jiang P; Hou Z
Medicine (Baltimore); 2023 Jun; 102(24):e34002. PubMed ID: 37327308
[TBL] [Abstract][Full Text] [Related]
7. Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis.
Yuan Y; Su Y; Wu Y; Xue Y; Zhang Y; Zhang Y; Zheng M; Chang T; Qu Y; Zhao T
Front Oncol; 2023; 13():1229905. PubMed ID: 37671057
[TBL] [Abstract][Full Text] [Related]
8. Global trends and research status in ankylosing spondylitis clinical trials: a bibliometric analysis of the last 20 years.
Zhang W; Li M; Li X; Wang X; Liu Y; Yang J
Front Immunol; 2023; 14():1328439. PubMed ID: 38288126
[TBL] [Abstract][Full Text] [Related]
9. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
Zhong H; Zhou J; Xu D; Zeng X
Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
[TBL] [Abstract][Full Text] [Related]
10. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.
Cappelli LC; Gutierrez AK; Bingham CO; Shah AA
Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
12. Bibliometric analysis of global research trends on male osteoporosis: a neglected field deserves more attention.
Wu H; Sun Z; Tong L; Wang Y; Yan H; Sun Z
Arch Osteoporos; 2021 Oct; 16(1):154. PubMed ID: 34632530
[TBL] [Abstract][Full Text] [Related]
13. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.
Dang QM; Watanabe R; Shiomi M; Fukumoto K; Nobashi TW; Okano T; Yamada S; Hashimoto M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982715
[TBL] [Abstract][Full Text] [Related]
14. Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis.
Song B; Lin Z; Feng C; Zhao X; Teng W
Front Endocrinol (Lausanne); 2023; 14():1252389. PubMed ID: 37795362
[TBL] [Abstract][Full Text] [Related]
15. Bibliometric study of immunotherapy for hepatocellular carcinoma.
Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
[TBL] [Abstract][Full Text] [Related]
16. Trends in immune-related adverse events for colorectal cancer: A bibliometric analysis.
Cui J; Xiong Y; Sun M; Gu X; Liu Y; Zhong L; Hong X; Liu L
Front Oncol; 2022; 12():1024321. PubMed ID: 36387099
[TBL] [Abstract][Full Text] [Related]
17. Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study.
Liu YG; Jiang ST; Zhang L; Zheng H; Zhang T; Zhang JW; Zhao HT; Sang XT; Xu YY; Lu X
Eur J Med Res; 2023 Jul; 28(1):229. PubMed ID: 37430294
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
19. Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.
Cheng K; Zhang H; Guo Q; Zhai P; Zhou Y; Yang W; Wang Y; Lu Y; Shen Z; Wu H
Front Immunol; 2022; 13():975695. PubMed ID: 36148235
[TBL] [Abstract][Full Text] [Related]
20. Publication trends of research on COVID-19 and host immune response: A bibliometric analysis.
Xia Y; Yao RQ; Zhao PY; Tao ZB; Zheng LY; Zhou HT; Yao YM; Song XM
Front Public Health; 2022; 10():939053. PubMed ID: 36003630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
